Wenbin Jiang, CEO and Chairman of the BoardA key hurdle hindering desired experimental outcomes revolves around effectively evaluating cell populations with high autofluorescence or low biomarker expression.
Flipping this script is Cytek® Biosciences, Inc.
Cytek’s innovative Full Spectrum Profiling™ (FSP™) technology allows for simultaneous multiplex measurements of 40 colors or more from a single tube. Offering unprecedented flexibility and time savings, FSP technology transforms flow cytometry, allowing scientists to use a wide range of fluorochrome combinations.
This high-parameter approach significantly improves traditional technologies, minimizing the time and resources spent on multiple tubes, assays, and reagents while reducing variability in small sample measurements.
FSP technology resolves and differentiates rare, dim, and challenging populations. With the autofluorescence extraction feature, users can define autofluorescence as separate or multiple parameters for resolving complex and highly autofluorescent populations.
FSP technology measures and identifies close or overlapping fluorescent emissions spectra in multicolor panels which allow for predictable fluorochrome interactions and effective panel design. This leads to increased data resolution for rare and dim populations with minimal spillover correction. Cytek also simplifies experiment setup and prevents incompatible filter errors with one configuration for all applications. Together, these innovations can help to accelerate the design of personalized immunotherapies that modulate the immune response against cancer cells, all important for cancer immunotherapy and translational research, where a breakthrough can transform lives.
“We are dedicated to empowering scientists and advancing next-generation cell analysis, and seek to foster accessibility and ease of use without compromising capabilities,” said Dr. Wenbin Jiang, CEO and chairman of the board, Cytek Biosciences, Inc. “By simplifying complex technologies, we allow researchers to channel their energy into what they do best – exploration and discovery.”
The Cytek® Aurora™ flow cytometer, which accommodates up to five lasers, three scatter channels, and 64 fluorescence channels, is powered by FSP technology and captures more detailed information from each fluorochrome regardless of the application complexity. Redefining sensitivity with state-of-the-art optics and low-noise electronics, the Cytek Aurora flow cytometer can detect low-abundance biomarkers and evaluate microparticles and extracellular vesicles (EVs) with high resolution and accuracy.
A testimonial by Dr. Ueno Hideki from Kyoto University emphasizes the impact of the Cytek Aurora analyzer. He stated, “The Cytek Aurora system is extremely useful for analyzing specimens in ultra-multicolor stained panels. Specimen processing, staining, and data capture are similar to those of conventional flow cytometers, making it easy to transfer between instruments. Another advantage is that, unlike mass cytometers, single-cell genetic analysis can be performed after cell sorting.”
Of note, the Cytek Aurora CS system was recently awarded the ‘Cell Sorting Product of the Year’ by BioTech Breakthrough. From over 1,500 nominations across 12 countries, it stood out as the only cell sorter on the market that combines FSP technology with high-performing cell sorting to help scientists better understand complex biological systems.
Another notable offering is the Cytek® Amnis® ImageStream®X Mk II imaging flow cytometer, which performs fluorescence analysis combined with single-cell imaging. Powerful artificial intelligence and machine learning-driven software seamlessly link images with quantitative data to define populations and cellular statuses. Users only need to click on a dot in any histogram to view corresponding images, click on a histogram bin to examine cells in the bin, and draw gates on dot plots and view the resulting populations to validate outcomes. The Cytek Amnis ImageStreamX Mk II system facilitates analysis of quantitative internalization, localization, cellular interactions, cellular exhaustion mechanisms, and cytotoxicity studies, opening new avenues for precise and insightful applications. In addition, for researchers focused on EVs, this instrument is highly sensitive and able to identify and resolve submicron particles.
We are dedicated to empowering scientists and advancing next-generation cell analysis, and we seek to foster accessibility and ease of use without compromising capabilities. By simplifying complex technologies, we allow researchers to channel their energy into what they do best – exploration and discovery
In addition to its more than 2,000 Cytek instruments deployed globally, Cytek has over 1,450 peer-reviewed publications featuring its FSP technology with applications across oncology, immunotherapy, drug and vaccine development, infectious diseases, and microparticle research.
In a testament to Cytek’s leadership, Dr. Manuel Ramirez from Madrid’s Hospital Infantil Universitario Niño Jesús commented, “Cancer treatment is an ever-evolving field, with clinical researchers and clinicians constantly striving to improve diagnostics and treatment. While flow cytometers have become a standard tool in our arsenal, Cytek is truly shaping the future of what is possible through cell analysis with its revolutionary spectral technologies.”
Recently, Cytek attained ISO 13485 certification for the design, manufacturing, and installation services of its products for its Fremont, California headquarters. The company’s manufacturing facilities in Wuxi, China are also EN ISO 13485 certified. Approved for clinical and diagnostic use in China and the EU, the company plans to expand its applications and propel the roadmap for translational and clinical markets in the U.S.
Poised to continue supporting translational and cancer immunology researchers in conducting cell profiling previously deemed impossible, Cytek’s comprehensive flow cytometry portfolio brings personalized treatments closer than ever before.
